Alaunos Therapeutics Newsroom

Should You Buy Alaunos Therapeutics Inc (TCRT) Stock on Friday?

Jan 8 09:10 ET

Alaunos Therapeutics Analyst Ratings

BenzingaAug 16, 2023 08:54 ET

H.C. Wainwright Downgrades Alaunos Therapeutics (TCRT) to a Hold

TipRanksAug 16, 2023 08:45 ET

Alaunos Therapeutics Analyst Ratings

BenzingaAug 15, 2023 10:42 ET

HC Wainwright & Co. Upgrades Alaunos Therapeutics to Buy, Announces $1.5 Price Target

BenzingaMay 15, 2023 07:21 ET

Alaunos Therapeutics (TCRT) Was Upgraded to a Buy Rating at H.C. Wainwright

TipRanksMay 15, 2023 06:15 ET

Wells Fargo Assumes Alaunos Therapeutics at Overweight, Announces Price Target of $3

BenzingaMar 27, 2023 09:54 ET

Wells Fargo Keeps Their Buy Rating on Alaunos Therapeutics (TCRT)

TipRanksMar 8, 2023 08:56 ET

Analysts Offer Insights on Healthcare Companies: Durect (DRRX), Alaunos Therapeutics (TCRT) and Marinus (MRNS)

TipRanksMar 8, 2023 08:41 ET

H.C. Wainwright Sticks to Their Hold Rating for Alaunos Therapeutics (TCRT)

TipRanksNov 15, 2022 06:46 ET

Alaunos Therapeutics Analyst Ratings

Benzinga Analyst RatingsOct 4, 2022 07:48 ET

Wells Fargo Assumes Alaunos Therapeutics at Overweight, Announces Price Target of $3

Benzinga Real-time NewsOct 4, 2022 07:48 ET

H.C. Wainwright Remains a Hold on Alaunos Therapeutics (TCRT)

TipRanksSep 7, 2022 06:31 ET

Cantor Fitzgerald Assumes Alaunos Therapeutics at Overweight with $3 Price Target

MT NewswiresJul 15, 2022 22:36 ET

Alaunos Therapeutics Price Target Announced at $3.00/Share by Cantor Fitzgerald

Dow JonesJul 15, 2022 08:49 ET

Alaunos Therapeutics analyst ratings

Benzinga Analyst RatingsJul 15, 2022 08:41 ET

Cantor Fitzgerald Assumes Alaunos Therapeutics at Overweight, Announces Price Target of $3

Benzinga Real-time NewsJul 15, 2022 08:40 ET